pI: 8.8693 |
Length (AA): 413 |
MW (Da): 48100 |
Paralog Number:
4
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
PDB Structures:
Ortholog group members (OG5_130162)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT3G17750 | protein kinase family protein |
Arabidopsis thaliana | AT1G73460 | putative serine/threonine kinase |
Arabidopsis thaliana | AT1G73450 | putative protein kinase |
Arabidopsis thaliana | AT2G40120 | putative serine/threonine protein kinase |
Babesia bovis | BBOV_III009650 | protein kinase domain containing protein |
Cryptosporidium hominis | Chro.70343 | dual-specificity tyrosine-(Y)-phosphorylation regulated kinase TbPK4 |
Cryptosporidium parvum | cgd7_3050 | protein kinase |
Giardia lamblia | GL50803_17558 | Kinase, CMGC DYRK |
Giardia lamblia | GL50803_137695 | Kinase, CMGC DYRK |
Leishmania braziliensis | LbrM.14.1060 | protein kinase, putative |
Leishmania braziliensis | LbrM.21.1940 | protein kinase, putative |
Leishmania donovani | LdBPK_212010.1 | protein kinase, putative |
Leishmania donovani | LdBPK_141140.1 | protein kinase, putative |
Leishmania infantum | LinJ.14.1140 | protein kinase, putative |
Leishmania infantum | LinJ.21.2010 | protein kinase, putative |
Leishmania major | LmjF.21.1650 | protein kinase, putative |
Leishmania major | LmjF.14.1070 | protein kinase, putative |
Leishmania mexicana | LmxM.14.1070 | protein kinase, putative |
Leishmania mexicana | LmxM.21.1650 | protein kinase, putative |
Neospora caninum | NCLIV_020950 | CMGC kinase, Dyrk family, putative |
Oryza sativa | 4327402 | Os01g0832900 |
Oryza sativa | 4333928 | Os03g0719500 |
Oryza sativa | 4339052 | Os05g0466900 |
Trypanosoma brucei gambiense | Tbg972.10.280 | protein kinase, putative |
Trypanosoma brucei gambiense | Tbg972.7.4330 | protein kinase, putative |
Trypanosoma brucei | Tb927.10.350 | protein kinase PK4, putative |
Trypanosoma brucei | Tb927.7.3880 | Basal body protein |
Trypanosoma congolense | TcIL3000_10_210 | protein kinase, putative |
Trypanosoma cruzi | TcCLB.510519.40 | protein kinase PK4, putative |
Trypanosoma cruzi | TcCLB.506869.60 | protein kinase PK4, putative |
Trypanosoma cruzi | TcCLB.511249.60 | CMGC/DYRK protein kinase, putative |
Toxoplasma gondii | TGME49_204280 | cell-cycle-associated protein kinase DYRK, putative |
Theileria parva | TP04_0880 | protein kinase, putative |
Trichomonas vaginalis | TVAG_000200 | CMGC family protein kinase |
Trichomonas vaginalis | TVAG_396210 | CMGC family protein kinase |
Trichomonas vaginalis | TVAG_048130 | CMGC family protein kinase |
Trichomonas vaginalis | TVAG_238860 | CMGC family protein kinase |
Trichomonas vaginalis | TVAG_362360 | CMGC family protein kinase |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.7.3880 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.7.3880 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb927.7.3880 | Trypanosoma brucei | significant loss of fitness in procyclic forms | alsford |
Tb927.7.3880 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
Tb927.10.350 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.10.350 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.10.350 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.10.350 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
TGME49_204280 | Toxoplasma gondii | Probably essential | sidik |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Species | Target | Length | Identity | Alignment span | Linked Drugs | Reference |
---|---|---|---|---|---|---|
Xenopus laevis | Aurora kinase B-A | 361 aa | 22.7% | 291 aa | Compounds | References |
Plasmodium falciparum (isolate 3D7) | Cell division control protein 2 homolog | 288 aa | 25.3% | 297 aa | Compounds | References |
Xenopus laevis | Aurora kinase B-B | 368 aa | 22.9% | 306 aa | Compounds | References |
Homo sapiens | Cyclin-dependent kinase 1/cyclin B1 | 297 aa | 28.3% | 293 aa | Compounds | References |
Rattus norvegicus | Cell division protein kinase 5 | 292 aa | 26.8% | 299 aa | Compounds | References |
Patiria pectinifera | Cdc2 | 300 aa | 28.2% | 294 aa | Compounds | References |
Rattus norvegicus | Mitogen-activated protein kinase 1 | 358 aa | 25.0% | 308 aa | Compounds | References |
Rattus norvegicus | MAP kinase p38 alpha | 360 aa | 26.6% | 293 aa | Compounds | References |